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Background. Prior epidemiologic studies suggest inverse relations between diabetes and glioma risk, but the underlying mecha-
nisms, including use of antidiabetic drugs, are unknown.
Methods. We therefore performed a matched case-control analysis using the Clinical Practice Research Datalink (CPRD). We iden-
tified incident glioma cases diagnosed between 1995 and 2012 and matched each case with 10 controls on age, gender, calendar
time, general practice, and years of active history in the CPRD. We performed conditional logistic regression to estimate odds ratios
(ORs) with 95% CIs, adjusted for body mass index and smoking.
Results. We identified 2005 cases and 20 050 controls. Diabetes was associated with decreased risk of glioma (OR¼ 0.74; 95%
CI¼ 0.60–0.93), particularly glioblastoma (OR¼ 0.69; 95% CI¼ 0.51–0.94). Glioblastoma risk reduction was markedly pro-
nounced among diabetic men (OR¼ 0.60; 95% CI¼ 0.40–0.90), most apparently for those with diabetes of long-term duration
(OR for.5 vs 0 y¼ 0.46; 95% CI¼ 0.26–0.82) or poor glycemic control (OR for HbA1c ≥8 vs,6.5%¼ 0.20; 95% CI¼ 0.06–0.70).
In contrast, the effect of diabetes on glioblastoma risk was absent among women (OR¼ 0.85; 95% CI¼ 0.53–1.36). No significant
associations with glioma were found for use of metformin (OR for ≥30 vs 0 prescriptions¼ 0.72; 95% CI¼ 0.38–1.39), sulfonyl-
ureas (OR¼ 0.71; 95% CI¼ 0.39–1.30), or insulin (OR¼ 0.79; 95% CI¼ 0.37–1.69).
Conclusions. Antidiabetic treatment appears to be unrelated to glioma, but long-term diabetes duration and increased HbA1c
both show decreased glioma risk. Stronger findings in men than women suggest low androgen levels concurrent with diabetes
as a biologic mechanism.
Keywords: diabetes, epidemiology, glioma, metformin, testosterone.
Malignant gliomas account for 80% of all primary malignant
tumors of the central nervous system, with a mean incidence
of 5–7 cases per 100 000 person-years.1 Gliomas can be sub-
divided according to their degree of malignancy into World
Health Organization (WHO) grades I–IV.2 The most common
and aggressive form is glioblastoma, which has a mean overall
survival of 14.6 months and a 2-year survival rate of 26.5%
with standard therapy.3 The few established risk factors for gli-
oma include age, male gender, Caucasian ethnicity, and certain
rare genetic syndromes. A high dose of ionizing radiation is the
only known modifiable glioma risk factor.4
Diabetes mellitus is a chronic disease affecting 347 million
people worldwide. Around 90% of diabetics suffer from type
2 diabetes, a condition of relative insulin deficiency and beta
cell dysfunction associated with obesity and metabolic syn-
drome.5 The relation of diabetes to glioma has been evaluated
in numerous previous studies, many6 – 11 of which reported a
statistically significant inverse association between the 2, but
several investigations showed statistically nonsignificant in-
verse,12 – 14 positive,15 null,16 – 19 or mixed20 relations. However,
these studies did not examine the association between diabe-
tes and glioma in detail.
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Furthermore, there is evidence to suggest that metformin,
one of the most widely prescribed oral antidiabetic drugs, re-
duces cancer risk in diabetic patients,21 and recent experimen-
tal data show distinct antiproliferative effects of metformin on
glioma cells in vitro and in vivo.22,23 However, the associations
between individual antidiabetic agents and glioma have not
been quantified. We therefore conducted a comprehensive ex-
amination of diabetes status, diabetes duration, glycemic con-
trol, and use of common antidiabetic agents (metformin,
sulfonylureas, and insulin) in relation to glioma risk using a
large, well-established primary care database.
Patients and Methods
Data Source
We used data from the UK-based Clinical Practice Research
Datalink (CPRD), which encompasses data on patients from
450 general practices representative of the UK population
with respect to age, gender, and geographic distribution. Gene-
ral practitioners record information regarding patient demo-
graphics, clinical diagnoses, referrals, hospital admissions,
and drug prescriptions using standard coding systems. Practi-
tioners generate prescriptions using office computers, and the
data are automatically recorded in the electronic patient re-
cords.24,25 The validity of the information on drug exposures
and diagnoses recorded in the CPRD database has been exten-
sively documented.26,27 The current study was approved by the
Independent Scientific Advisory Committee for the UK Medi-
cines and Healthcare Products Regulatory Agency.
Study Population
Case Definition
Cases were defined as all patients in the CPRD database below
age 90 years with an incident glioma diagnosis between 1995
and 2012. The date of the first-time diagnosis, as defined using
Read codes, will be referred to as the index date. Read codes for
glioma are based on histopathology according to the WHO
classification2 (Supplementary Table 1). We excluded patients
with any prior history of cancer other than glioma except non-
melanoma skin cancer, those with alcoholism or human immu-
nodeficiency virus infection prior to the index date, and patients
with less than 3 years of active history in the database prior to
the index date. We considered total glioma and glioma accord-
ing to WHO grade (grade IV only, grade III or IV, and grade II).
We did not compare patients with grade I glioma to those with
other WHO grades because these tumors have a distinct path-
ogenesis and affect mostly pediatric patients.1,2
Control Definition
We randomly selected up to 10 controls without a glioma his-
tory from the CPRD and matched them to glioma cases on cal-
endar time (same index date), age (same year of birth), gender,
general practice, and years of medical history in the database
prior to the index date. The selection of controls was based on
the same inclusion and exclusion criteria used for glioma cases.
To minimize the risk of using control patients with misclassified
glioma, we excluded control patients with a prior history of
craniotomy within the past year before the index date, a time
window considered sufficient given malignant glioma’s highly
invasive phenotype.
Exposures
Using the computerized CPRD records, we assessed diabetes sta-
tus and diabetes duration. We also considered the mean hemo-
globin A1c (HbA1c) level during the past 3 years prior to the index
date as a proxy for long-term glycemic control. Diabetes status
(yes or no) was defined using specific Read codes reflecting diag-
nostic criteria for diabetes in the UK in the respective time period.
We defined diabetes duration as the time interval between the
date of the first diabetes recording and the index date. Diabetes
duration was classified into 3 categories (,2, 2–5,.5 y). HbA1c
level was also classified into 3 categories (,6.5, 6.5–7.9, ≥8%).
Missing values were included in a separate category.
Exposure to antidiabetic drugs was categorized based on
the number of prescriptions prior to the index date. Subjects
who did not receive any prescription for an antidiabetic drug
prior to the index date were categorized as non-users. For sub-
jects using more than one antidiabetic drug, we mutually ad-
justed for sequential or concurrent use in the multivariate
model. Antidiabetic drug users were categorized according to
short-term use (1– 9 prescriptions prior to the index date),
medium-term use (10 –29 prescriptions prior to the index
date), or long-term use (≥30 prescriptions prior to the index
date). The number of prescriptions served as a proxy for expo-
sure duration, since an average prescription covers 45 –90
treatment days. Users of metformin, sulfonylureas, and insulin
were examined separately.
Statistical Analysis
We conducted conditional logistic regression analyses to deter-
mine relative risks, estimated as odds ratios (ORs) with 95%
confidence intervals (CIs) of glioma in relation to diabetes sta-
tus, diabetes duration, HbA1c level, and individual antidiabetic
drug use. Potential confounding variables included body mass
index (BMI; ,18.5, 18.5 –24.9, 25 –29.9, ≥30.0 kg/m2, un-
known); smoking status (never, current, past, unknown); car-
diovascular conditions or diseases (dyslipidemia, stroke/
transient ischemic attack, hypertension, congestive heart fail-
ure, ischemic heart disease, myocardial infarction, chronic
renal failure); and use of statins (0, 1–9, ≥10 prescriptions),
nonsteroidal anti-inflammatory drugs (NSAIDs; 0, 1–9, ≥10
prescriptions), aspirin (0, 1–14, ≥15 prescriptions), and estro-
gens (0, 1–14, ≥15 prescriptions; women only). Variables that
altered the effect estimate for glioma by.10% in the multivar-
iate analyses were retained in the model. Our final model
included BMI and smoking. Tests of linear trend were conduct-
ed by modeling the median value of each category as a contin-
uous variable in the multivariate model, the coefficient for
which was evaluated using a Wald test.
To assess treatment prior to disease onset, to control for
changes in antidiabetic treatment over time, and to account
for potential earlier detection of preexisting diabetes in case pa-
tients caused by early symptoms of undiagnosed glioma, for all
analyses we shifted the index date backward in time by one
year for cases and controls.
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We further assessed the role of antidiabetic drug use in re-
lation to glioma in a subsample restricted to diabetic cases and
controls. In these analyses, we newly matched diabetic glioma
cases with diabetic cancer-free controls on duration of diabetes
to control for duration-related biases. In a further sensitivity
analysis, we additionally matched on both duration of diabetes
and HbA1c level to account for the influence of glycemic con-
trol on the choice of antidiabetic treatment. The intended 1:10
matching was not fully achieved in these sensitivity analyses
due to limited numbers.
To examine whether the associations of diabetes status, di-
abetes duration, HbA1c level, and antidiabetic drug use were
modified in relation to glioma risk, we evaluated glioma risk
within strata of gender (men, women) and age (,67, ≥67 y).
We chose a cutpoint of 67 years because this was the median
age of diabetic glioma patients. We conducted formal tests for
interaction using likelihood ratio tests. For all statistical analy-
ses, the type I error was set at 5% and tests were 2-tailed.
We used SAS statistical software version 9.2.
Results
We identified 2005 incident glioma cases and 20 050 matched
controls in the CPRD database. Of these, slightly over half
(55.2%) were men. The mean age (+SD) for cases and controls
was 55.5 (+18.7) years. The mean number of years of active
history in the database for cases and controls was 10.6
(+4.7) years. Among those with available information on
WHO glioma grade (1138 patients; 56.8% of total), 66 patients
were diagnosed as grade I (5.8%), 152 patients as grade II
(13.4%), 68 patients as grade III (6.0%), and 852 patients as
grade IV glioma (74.9%).
Characteristics of glioma cases and controls are displayed in
Table 1. In crude analyses, current versus never smoking (OR¼
0.87; 95% CI¼ 0.76–0.99) and a history of congestive heart fail-
ure (OR¼ 0.58; 95% CI¼ 0.37–0.91) were associated with de-
creased glioma risk. Underweight (,18.5 kg/m2) versus normal
weight (18.5–24.9 kg/m2) was also inversely related to glioma
(OR¼ 0.53; 95% CI¼ 0.30–0.93). In contrast, history of dyslipi-
demia, stroke, hypertension, ischemic heart disease, myocardial
infarction, renal failure, and use of statins, NSAIDs, aspirin, and
estrogens (among women) were unrelated to glioma.
Among the 2005 glioma cases and 20 050 controls, we
identified 96 (5%) and 1240 (6%) patients, respectively, with di-
abetes, which is consistent with diabetes prevalence in the UK
population of a comparable age range.28 The mean age of di-
abetic glioma patients was 66.4 (+10.4) years. There were only
2 cases (2.1% of all diabetic cases) and 33 controls (2.7% of all
diabetic controls) who were classified as having type 1 diabetes
(defined as patients with the combination of incident diabetes
diagnosis below age 30 plus documented insulin use).
Having diabetes was associated with a decreased risk of
glioma (adjusted OR¼ 0.74; 95% CI¼ 0.60–0.93) (Table 2).
When analyzed by gender, the risk of total glioma was slightly
more pronounced in men (OR¼ 0.70; 95% CI¼ 0.53–0.92)
than women (OR¼ 0.84; 95% CI¼ 0.59–1.19), although the dif-
ference was not statistically significant (P-value for interaction
by gender¼ .306). The risk of diabetes in relation to total glioma
did not vary by age (P-value for interaction by age¼ .836).
When we restricted the analysis to the subset of 852
patients with glioblastoma (grade IV glioma), the OR was
0.69 (95% CI¼ 0.51–0.94) among those with diabetes com-
pared with those without. Similar to total glioma, the associa-
tion between diabetes and glioblastoma was stronger in men
(OR¼ 0.60; 95% CI¼ 0.40– 0.90) than women (OR¼ 0.85;
95% CI¼ 0.53 –1.36). In addition, there was a suggestion
of a more pronounced effect in older (OR¼ 0.54; 95%
CI¼ 0.34– 0.85) than younger subjects (OR¼ 0.87; 95%
CI¼ 0.57– 1.32; P-value for interaction by age¼ .138). The
association between diabetes and grade III or IV glioma was
similar to that for total glioma. No association was found
between diabetes and grade II glioma, but the number of
grade II glioma cases with diabetes was limited (Table 2).
Upon stratification by estrogen use, there was no effect of
diabetes on the risk of glioma among women not exposed to
estrogens (OR¼ 0.99; 95% CI¼ 0.67–1.46), whereas estrogen-
exposed women had a strong but not statistically significant
inverse effect on risk due to small numbers (OR¼ 0.34; 95%
CI¼ 0.10–1.13, based on 5 female diabetic cases and 105
female diabetic controls exposed to estrogens).
To address whether the relation of diabetes to glioma was
confounded by antidiabetic treatment, we evaluated the asso-
ciation between diabetes and glioma after adjusting for antidi-
abetic drugs. The relation of diabetes to glioma was slightly
attenuated after adding sulfonylureas to the model (OR for
diabetes¼ 0.86; 95% CI¼ 0.65–1.14), but it was unaffected
by inclusion of metformin, insulin, or other antidiabetic drugs
in the model (ORs for diabetes¼ 0.72, 0.78, and 0.70,
respectively).
We next investigated the association between diabetes
duration and glioma (Table 3). Long duration of diabetes had
an inverse association with total glioma (OR¼ 0.67; 95% CI¼
0.50–0.90; P-value for trend¼ .006). When analyzed according
to WHO glioma grade, long-term diabetes duration was
inversely associated with grade IV glioma (OR¼ 0.57; 95%
CI¼ 0.37–0.87) and grade III or IV glioma (OR¼ 0.62; 95%
CI¼ 0.41– 0.94), but not with grade II glioma (OR¼ 1.53;
95% CI¼ 0.58–4.05; P-value for interaction by WHO grade¼
.019). Additional stratification of grade IV glioma analyses by
gender yielded ORs for long-term diabetes duration of 0.46
(95% CI¼ 0.26 –0.82) for men and 0.81 (95% CI¼ 0.41–
1.58) for women (P-value for interaction by gender¼ .198).
We also examined the association between glycemic control
and risk of glioma (Table 3). As compared with HbA1c ,6.5%,
HbA1c ≥8.0% was associated with a strong reduction in total
glioma risk (OR¼ 0.57; 95% CI¼ 0.33–0.96). Risk reduction ap-
peared to be most pronounced for grade IV glioma (OR¼ 0.52;
95% CI¼ 0.25–1.09), though also present for grade III or IV gli-
oma (OR¼ 0.62; 95% CI¼ 0.31–1.24), but not grade II glioma
(OR¼ 0.96; 95% CI¼ 0.16 –5.74; P-value for interaction by
WHO grade¼ .058). Similarly, when the analysis was restricted
to diabetic patients, high versus low HbA1c level was inversely
associated with glioma (OR¼ 0.34; 95% CI¼ 0.10–1.22), par-
ticularly grade IV glioma (OR¼ 0.12; 95% CI¼ 0.01–1.22), but
those effect estimates did not reach statistical significance.
When stratified by gender, the risk associated with poor gly-
cemic control was stronger in men (OR for total glioma¼ 0.40;
95% CI¼ 0.19–0.81) and strongest among glioblastoma cases
(OR¼ 0.20; 95% CI¼ 0.06– 0.70). High HbA1c was not
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Table 1. Characteristics of glioma cases and controls
Variable Number of Cases (%) (n¼ 2005) Number of Controls (%) (n¼ 20 050) Crude OR (95% CI) P
Age, ya
0–9 63 (3.14) 630 (3.14) – –
10–19 74 (3.69) 740 (3.69) – –
20–29 87 (4.34) 870 (4.34) – –
30–39 137 (6.83) 1370 (6.83) – –
40–49 215 (10.72) 2150 (10.72) – –
50–59 454 (22.64) 4540 (22.64) – –
60–69 503 (25.09) 5030 (25.09) – –
70–79 368 (18.35) 3680 (18.35) – –
80–90 104 (5.19) 1040 (5.19)
Sexa
Men 1106 (55.16) 11 060 (55.16) – –
Women 899 (44.84) 8990 (44.84) – –
BMI (kg/m2)
,18.5 13 (0.65) 236 (1.18) 0.53 (0.30–0.93) .026
18.5–24.9 604 (30.12) 5780 (28.83) 1.00 (referent) –
25–29.9 611 (30.47) 5833 (29.09) 1.00 (0.89–1.13) .968
≥30.0 307 (15.31) 3133 (15.63) 0.94 (0.81–1.08) .382
Unknown 470 (23.44) 5068 (25.28) 0.89 (0.78–1.01) .064
Smoking status
Never smoker 970 (48.38) 8976 (44.77) 1.00 (referent) –
Current smoker 322 (16.06) 3440 (17.16) 0.87 (0.76–0.99) .033
Past smoker 434 (21.65) 4358 (21.74) 0.92 (0.82–1.04) .178
Unknown 279 (13.92) 3276 (16.34) 0.79 (0.69–0.91) .001
Comorbidities
Dyslipidemia 168 (8.38) 1778 (8.87) 0.94 (0.80–1.11) .462
Stroke/TIA 74 (3.69) 731 (3.65) 1.01 (0.79–1.29) .918
Hypertension 469 (23.39) 4663 (23.26) 1.01 (0.90–1.12) .892
CHF 20 (1.00) 343 (1.71) 0.58 (0.37–0.91) .018
IHD 168 (8.38) 1725 (8.60) 0.97 (0.82–1.15) .735
MI 55 (2.74) 695 (3.47) 0.79 (0.60–1.04) .090
Renal failure 53 (2.64) 440 (2.19) 1.21 (0.91–1.62) .195
Statins
No prior use 1715 (85.54) 17 133 (85.45) 1.00 (referent) –
1–9 Rx 79 (3.94) 797 (3.98) 0.99 (0.78–1.25) .935
≥10 Rx 211 (10.52) 2120 (10.57) 0.99 (0.86–1.16) .941
NSAIDs
No prior use 658 (32.82) 6500 (32.42) 1.00 (referent) –
1–9 Rx 1255 (62.59) 12 688 (63.28) 0.98 (0.89–1.08) .646
≥10 Rx 92 (4.59) 862 (4.30) 1.05 (0.84–1.33) .651
Aspirin
No prior use 1950 (97.26) 19 440 (96.96) 1.00 (referent) –
1–14 Rx 35 (1.75) 446 (2.22) 0.78 (0.55–1.11) .166
≥15 Rx 20 (1.00) 164 (0.82) 1.22 (0.76–1.94) .412
Estrogensb
No prior use 677 (75.31) 6781 (75.43) 1.00 (referent) –
1–14 Rx 146 (16.24) 1477 (16.43) 0.99 (0.82–1.19) .918
≥15 Rx 76 (8.45) 732 (8.14) 1.04 (0.81–1.34) .754
Abbreviations: TIA, transient ischemic attack; CHF, congestive heart failure; IHD, ischemic heart disease; MI, myocardial infarction; Rx, total number
of prescriptions prior to index date.
aMatching variables: age, sex, general practice, and number of years of active history in the database.
bWomen only.
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associated with risk of glioma in women (total glioma
OR¼ 0.95; 95% CI¼ 0.42–2.13; glioblastoma OR¼ 1.36; 95%
CI¼ 0.48–3.84, P-value for interaction by gender¼ .160).
We also examined the associations between use of antidia-
betic medications and glioma (Table 4). As compared with no
prior use of metformin, increasing dosages of metformin yielded
no clear association with glioma, although there was a sugges-
tion of an association in the highest dose category. The ORs for
1–9, 10–29, and ≥30 prescriptions were 1.11, 1.42, and 0.72,
respectively (95% CI¼ 0.38–1.39) (P-value for trend¼ .283). In-
verse but statistically nonsignificant associations were observed
with sulfonylurea use (corresponding ORs¼ 0.71, 0.58, and 0.71;
95% CI¼ 0.39–1.30; P-value for trend¼ .291) and insulin use
(ORs¼ 0.96, 0.63, and 0.79; 95% CI¼ 0.37–1.69; P-value for
trend¼ .498).
To control for the effects of diabetes duration and glycemic
control, we restricted an analysis to diabetic glioma cases and
diabetic controls and matched on diabetes duration and HbA1c
level. Results for long-term use of metformin (OR¼ 0.58; 95%
CI¼ 0.24–1.44) and insulin (OR¼ 0.68; 95% CI¼ 0.11–4.27)
remained consistent with those from our main analysis. How-
ever, the previous inverse relation of long-term sulfonylurea use
to total glioma was rendered positive in this matched analysis
(OR¼ 1.76; 95% CI¼ 0.76–4.09).
Discussion
In this large, population-based case-control analysis, we ob-
served a statistically significant inverse relation between history
of diabetes and subsequent risk of glioma, particularly glioblas-
toma. The inverse association was most evident for long-
standing or poorly controlled diabetes. We found no statistically
significant associations of treatment with metformin, sulfonyl-
ureas, or insulin to glioma risk. This indicates that the observed
Table 2. Risk of glioma in relation to diabetes status, overall and stratified by gender, age, and glioma grade
Variable Number of Cases (%) Number of Controls (%) Adjusted ORa (95% CI)
Total glioma n¼ 2005 n¼ 20 050
Diabetes 96 (4.79) 1240 (6.18) 0.74 (0.60–0.93)
Stratification by gender
Men 59 (61.46) 819 (66.05) 0.70 (0.53–0.92)
Women 37 (38.54) 421 (33.95) 0.84 (0.59–1.19)
Stratification by age
,67 y 46 (47.91) 583 (47.02) 0.75 (0.54–1.02)
≥67 y 50 (52.08) 657 (52.98) 0.75 (0.55–1.01)
Glioblastoma n¼ 852 n¼ 8520
Diabetes 48 (5.63) 667 (7.83) 0.69 (0.51–0.94)
Stratification by gender
Men 27 (56.25) 428 (64.17) 0.60 (0.40–0.90)
Women 21 (43.75) 239 (35.83) 0.85 (0.53–1.36)
Stratification by age
,67 y 27 (56.25) 306 (45.88) 0.87 (0.57–1.32)
≥67 y 21 (43.75) 361 (54.12) 0.54 (0.34–0.85)
Grade III or IV glioma n¼ 920 n¼ 9200
Diabetes 53 (5.76) 693 (7.53) 0.74 (0.55–0.99)
Stratification by gender
Men 30 (56.60) 448 (64.64) 0.64 (0.44–0.95)
Women 23 (43.40) 245 (35.35) 0.91 (0.58–1.44)
Stratification by age
,67 y 30 (56.60) 324 (46.75) 0.92 (0.62–1.37)
≥67 y 23 (43.40) 369 (53.25) 0.58 (0.37–0.91)
Grade II glioma n¼ 152 n¼ 1520
Diabetes 7 (4.61) 64 (4.21) 1.12 (0.49–2.56)
Stratification by gender
Men 6 (85.70) 39 (60.94) 1.57 (0.61–4.02)
Women 1 (14.29) 25 (30.06) 0.42 (0.06–3.21)
Stratification by age
,67 y 5 (71.43) 46 (71.88) 1.14 (0.44–2.98)
≥67 y 2 (28.57) 18 (28.13) 1.04 (0.21–5.20)
The %-values in the stratification groups refer to the diabetic subcohort.
Information on glioma grade was missing for 867 glioma patients. The median age of diabetic glioma patients was 67 years.
aMatched on age, sex, general practice, number of years of active history in the database, and adjusted for BMI and smoking.
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decreased glioma risk among diabetics is not likely due to
medications taken to treat diabetes, but rather to diabetes
itself.
The first paper that found a lower frequency of intracranial
neoplasms in diabetic patients was published in 1965.29 Since
then, 3 prospective studies6 – 8 and 6 case-control studies9 – 14
found statistically significant6 – 11 or nonsignificant12 – 14 inverse
associations between diabetes and risk of glioma6,9 – 14 or brain
cancer.7,8 In contrast, one prospective study15 reported a stat-
istically nonsignificant positive relation of diabetes to glioma,
and another prospective study20 noted a statistically significant
positive association with brain cancer in women, whereas the
relation was null in men. Three additional prospective stud-
ies16 – 18 and one case-control study19 observed no association
between diabetes and brain cancer.
Our observation of a stronger apparent protective effect
against glioma with increasing diabetes duration is consistent
with one cohort8 and one case-control study9 that found signif-
icantly decreased glioma risk with longer time since diabetes
diagnosis. In contrast, one case-control study observed no as-
sociation with diabetes duration.10 That study, however, was
based on hospital discharge diagnoses of diabetes and may
have encompassed fewer patients with early stages of diabe-
tes. Insufficient variation at the low end of the diabetes severity
spectrum may have limited the ability of that study to detect a
relation with diabetes duration.
Our study is the first to suggest that poor glycemic control,
as assessed by elevated HbA1c level, is associated with de-
creased glioma risk. One prospective study30 found an inverse
relation of blood glucose levels to brain cancer in men and a
statistically nonsignificant positive association in women.
Another prospective study31 found a suggestive positive associ-
ation between blood glucose levels and brain cancer in Korean
men. However, both these investigations30,31 lacked specification
on the type of brain cancer. Also, blood glucose levels are a poor
proxy for glycemic control because they only capture glucose
levels at the time measured and are sensitive to various other
factors, such as food intake and physical activity.32
The current study is the first to comprehensively explore in-
dividual antidiabetic agents in relation to glioma. Our results do
not strongly support the proposition that the inverse relation of
diabetes to glioma is explained by antidiabetic treatment.
We found, however, that the highest category of metformin
duration was associated with statistically nonsignificantly re-
duced glioma risk (OR¼ 0.72; 95% CI¼ 0.38–1.39). The asso-
ciation became stronger after matching on duration of diabetes
and HbA1c (OR¼ 0.58; 95% CI¼ 0.24–1.44), indicating that bi-
ases related to disease duration and glycemic control do not
account for the observed relations. This is consistent with a
number of laboratory investigations showing antitumorigenic
effects of metformin on tumor cells and established tumors
in animal models.22,23 However, our data are not directly
Table 3. Risk of glioma in relation to duration of diabetes and HbA1c level
Variable Number of Cases (%) Number of Controls (%) Adjusted ORa (95% CI)
Total glioma n¼ 2005 n¼ 20 050
Duration of diabetes, y
Nondiabetic 1909 (95.21) 18 810 (93.82) 1.00 (referent)
,2 21 (1.05) 237 (1.18) 0.85 (0.54–1.34)
2–5 25 (1.25) 290 (1.45) 0.83 (0.55–1.26)
.5 50 (2.49) 713 (3.56) 0.67 (0.50–0.90)
P-value for trend .006
HbA1c level
Unknown 1893 (94.41) 18 749 (93.51) 0.97 (0.71–1.32)
,6.5% 48 (2.39) 451 (2.25) 1.00 (referent)
6.5%–7.9% 42 (2.09) 488 (2.43) 0.81 (0.52–1.25)
≥8.0% 22 (1.10) 362 (1.81) 0.57 (0.33–0.96)
P-value for trend .070
Total glioma, diabetic patients only n¼ 96 n¼ 1240
Duration of diabetes, y
,2 21 (21.88) 237 (19.11) 1.00 (referent)
2–5 25 (26.04) 290 (23.39) 0.65 (0.22–1.91)
.5 50 (52.08) 713 (57.50) 0.62 (0.23–1.66)
P-value for trend .446
HbA1c level
Unknown 11 (11.46) 177 (14.27) 1.17 (0.11–12.42)
,6.5% 22 (22.92) 243 (19.60) 1.00 (referent)
6.5%–7.9% 41 (42.71) 463 (37.34) 0.71 (0.27–1.87)
≥8.0% 22 (22.92) 357 (28.79) 0.34 (0.10–1.22)
P-value for trend .091
aMatched on age, sex, general practice, and number of years of active history in the database, and adjusted for BMI and smoking. The P-value for
trend did not include subjects with unknown HbA1c level.
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Table 4. Risk of glioma in relation to number of prescriptions for antidiabetic drugs
Antidiabetic Drug
and No. of
Prescriptions
Glioma Cases and Controls Diabetic Glioma Cases and Controls, Matched on
Duration of Diabetes
Diabetic Glioma Cases and Controls, Matched on
Duration of Diabetes and HbA1c Level
Cases (%)
(n¼ 2005)
Controls (%)
(n¼ 20 050)
Adjusted ORa,b
(95% CI)
Cases (%)
(n¼ 93)
Controls (%)
(n¼ 842)
Adjusted ORa
(95% CI)
Cases (%)
(n¼ 86)
Controls (%)
(n¼ 598)
Adjusted ORa
(95% CI)
Metformin
0 1948 (97.16) 19 334 (96.43) 1.00 (referent) 38 (40.86) 354 (42.04) 1.00 (referent) 35 (40.70) 295 (49.33) 1.00 (referent)
1–9 14 (0.70) 170 (0.85) 1.11 (0.59–2.12) 12 (12.90) 120 (14.25) 0.97 (0.47–2.02) 11 (12.79) 78 (13.04) 1.07 (0.47–2.40)
10–29 23 (1.15) 216 (1.08) 1.42 (0.81–2.47) 23 (24.73) 146 (17.34) 1.40 (0.74–2.67) 21 (24.42) 123 (20.57) 1.06 (0.53–2.11)
≥30 20 (1.00) 330 (1.65) 0.72 (0.38–1.39) 20 (21.51) 222 (26.37) 0.63 (0.29–1.34) 19 (22.09) 102 (17.06) 0.58 (0.24–1.44)
P-value for trend .283 .237 .229
Sulfonylureas
0 1966 (98.05) 19 447 (96.99) 1.00 (referent) 54 (58.06) 491 (58.31) 1.00 (referent) 50 (58.14) 407 (68.06) 1.00 (referent)
1–9 9 (0.45) 131 (0.65) 0.71 (0.34–1.49) 9 (9.68) 85 (10.10) 1.07 (0.47–2.43) 9 (10.47) 53 (8.86) 1.32 (0.54–3.26)
10–29 10 (0.50) 182 (0.91) 0.58 (0.29–1.18) 10 (10.75) 122 (14.49) 0.75 (0.34–1.66) 8 (9.30) 70 (11.71) 0.87 (0.36–2.09)
≥30 20 (1.00) 290 (1.45) 0.71 (0.39–1.30) 20 (21.51) 144 (17.10) 1.35 (0.65–2.80) 19 (22.09) 68 (11.37) 1.76 (0.76–4.09)
P-value for trend .291 .453 .271
Insulin
0 1991 (99.30) 19 819 (98.85) 1.00 (referent) 81 (87.10) 714 (84.80) 1.00 (referent) 78 (90.70) 553 (92.47) 1.00 (referent)
1–9 3 (0.15) 41 (0.20) 0.96 (0.28–3.27) 3 (3.23) 27 (3.21) 0.76 (0.21–2.76) 3 (3.49) 14 (2.34) 0.77 (0.17–3.47)
10–29 3 (0.15) 58 (0.29) 0.63 (0.19–2.10) 3 (3.23) 43 (5.11) 0.63 (0.18–2.25) 2 (2.33) 14 (2.34) 0.90 (0.17–4.79)
≥30 8 (0.40) 132 (0.66) 0.79 (0.37–1.69) 6 (6.45) 58 (6.89) 0.62 (0.20–1.95) 3 (3.49) 17 (2.84) 0.68 (0.11–4.27)
P-value for trend .498 .391 .659
aMatched on age, sex, general practice, and number of years of active history in the database, and adjusted for BMI, smoking, and all antidiabetics used by the study population.
bAdditionally adjusted for diabetes status.
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comparable to laboratory studies, which examined the effect of
metformin on tumor progression and not tumor incidence and
used metformin dosages that often greatly exceeded the levels
achievable in humans.
Possible underlying biologic mechanisms of a protective ef-
fect of diabetes on glioma development are poorly understood.
Advanced stages of diabetes mellitus are associated with lower
levels of circulating insulin and insulin-like growth factor 1
(IGF-1) and higher levels of IGF binding protein 3 (IGFBP-3).33
IGFs possess anabolic functions in astrocytes and neurons
and show enhanced expression in glioma.34 Moreover, IGF-1
has mitogenic potential in glioma cells, and antisense strate-
gies against IGF-1 have been tested for clinical use as antitu-
mor treatment.34 Therefore, decreased signaling via insulin
and IGFs represent a potential pathway to explain the observed
apparent protective effect of diabetes on glioma. However, a
previous study relating IGF-1 and IGFBP-3 to glioma risk failed
to support this hypothesis.35 We therefore discuss potential ad-
ditional mechanisms in greater detail.
In our study, the inverse association between diabetes and
glioblastoma was more apparent in men than women, and it
was more pronounced in older than younger individuals. Age
and gender-specific hormonal changes in diabetic individuals
could serve as a possible explanation. For example, gliomas
are more frequent in men than women, and an underlying ef-
fect of testosterone was argued as early as the 1950s.36 Since
then, the testosterone hypothesis has been largely neglected
and the gender difference in glioma incidence was mainly at-
tributed to protective female reproductive factors.37
We hypothesize that testosterone plays a role in mediating
the inverse association between diabetes and glioma in men.
Early laboratory studies reported that castrated male rats
showed significantly lower incidence and delayed onset of
brain tumors than uncastrated male rats.38,39 More recently,
in vitro studies have found that testosterone increases tumor
cell proliferation in glioma cells40 and modulates the
phosphatidylinositol-3 kinase/Akt and mitogen-activated pro-
tein kinase signaling cascade, forming major oncogenic path-
ways in glioma.41 Androgens, as steroid hormones, easily
pass the blood–brain barrier, and glioma cells frequently ex-
press androgen receptors.41
Human studies show that metabolic syndrome and type 2
diabetes are strongly linked to lower androgen levels in men,
with an increased prevalence of hypogonadism of up to 50%
in men with type 2 diabetes mellitus.42 Age-related hypogo-
nadism in men, also referred to as andropause, is an estab-
lished clinical syndrome, with serum testosterone levels
,11 nmol/L and clinical symptoms including decreased libido,
erectile dysfunction, depression, and fatigue, conditions that
are also common among diabetic patients.43 Diabetes and as-
sociated lower androgen levels are also related to reduced
prostate cancer incidence, a malignancy on which the effects
of androgens are well established.44
In contrast to their male counterparts, postmenopausal
women with type 2 diabetes have increased levels of both bio-
available estradiol and testosterone.45 In women, hormonal
contraception, which often includes anti-androgenic substanc-
es, reduces risk of glioma.37 In our study, diabetic women with
estrogen use had a markedly stronger reduction in glioma risk
than diabetic women without estrogen use. Conceivably,
certain hormonal changes associated with diabetes in
women could lower glioma risk (eg, increased circulating levels
of estrogen), whereas others could enhance risk (eg, increased
levels of testosterone). The null association we observed be-
tween diabetes and glioma in women may be explained by
the possibility that the protective effects of increased estrogen
were partially offset by the adverse effects of increased
testosterone.
Our observation that glioma risk was more pronounced in
grade IV than grade I or II gliomas may partly be accounted
for by the different ages of onset of these malignancies. High-
grade gliomas occur later in life than low-grade gliomas, which
increases the amount of time needed for long-term diabetes to
confer its protective effects. In addition, physiological hormonal
changes in older men, such as waning testosterone levels, may
be amplified by diabetes-induced decreases in testosterone.
Our observation that glioma risk decreased with increasing
diabetes duration may be explained by the fact that in men,
early stages of type 2 diabetes are accompanied by hyperinsu-
linemia, which is associated with reduced IGFBP-3 and sex hor-
mone binding globulin (SHBG), and consequently enhanced
IGF-1 and testosterone. However, as diabetes progresses to
hypoinsulinemic stages, IGFBP-3 and SHBG levels increase,
and IGF-1 and bioavailable testosterone levels decrease.33
Also, poor glycemic control is associated with a decline in
ß-cell function.46
Previous investigators have attempted to explain the in-
verse relation of diabetes to glioma with a mechanism related
to allergy and autoimmune diseases,8,9,11,14 with inflamma-
tion also contributing to the pathogenesis of type 2 diabetes.47
A further explanation for the observed decreased glioma risk
associated with diabetes is the presence of diabetes-related
single nucleotide polymorphisms (SNPs) inversely related to
glioma. While genetic susceptibility to diabetes may play a cer-
tain role in glioma risk, the currently sparse data available
point toward null associations between known diabetes SNPs
and glioma.11
Certain potential shortcomings of our study should be men-
tioned. The inverse association between diabetes and glioma
may be confounded by factors associated with both glioma
and diabetes, such as a sedentary lifestyle, obesity, smoking,
and lower socioeconomic status. However, cases and controls
were matched on general practice, which at least partially con-
trols for socioeconomic status, and we adjusted for BMI and
smoking. We were unable to control for physical activity or
other lifestyle factors, but prior studies suggested no meaningful
associations between adulthood lifestyle factors and glioma
risk.48 Our findings may not apply to non-Caucasian populations
because 86% of individuals in our database were Caucasian.49
Our study has numerous strengths. We used a large, longi-
tudinal, well-established, and validated database.25 – 27 Our
study is not likely prone to selection bias because both glioma
cases and randomly selected controls were generated from the
CPRD. Also, our study is free from recall bias because the data
regarding medical conditions and medications were collected
prospectively. In addition, potential diagnostic bias caused by
an earlier diagnosis of diabetes among those with early symp-
toms of undiagnosed glioma was minimized by shifting the
index date back by one year. Further, we conducted a large
number of informative sensitivity analyses. Finally, only
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patients with an active history of at least 3 years in the CPRD
database were included in the current study, which likely im-
proved the quality and quantity of patient information due to
more frequent practice visits among those subjects.
In summary, we observed an inverse relation between dia-
betes and risk of glioma, an association that was most pro-
nounced among those with long-term and poorly controlled
diabetes. In addition, the apparent protective effect of diabetes
on glioma development appeared to be stronger in men than
women, and in older than younger individuals. Antidiabetic
medications were unrelated to glioma, but a potential protec-
tive effect of heavy metformin use on glioma risk cannot be en-
tirely excluded. Our findings raise the possibility that lower
androgen levels, concurrent with type 2 diabetes, have a pro-
tective effect on risk of glioma.
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